Thereby, c-KIT has been implicated in the pathogenesis of several cancers including metastatic melanoma [57, 58], and previous clinical trials demonstrated a durable overall RR (16–24%) as well as a median OS ranging from 11 to 14 months [50, 53, 59]. This evidence concerns the gene KIT and metastatic melanoma.